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Real-World Lessons From the Implementation of a
Depression Screening Protocol in Acute Myocardial
Infarction Patients
Implications for the American Heart Association Depression
Screening Advisory
Kim G. Smolderen, PhD; Donna M. Buchanan, PhD; Alpesh A. Amin, MD;
Kensey Gosch, MS; Karen Nugent, RRT; Lisa Riggs, RN, MSN, ACNS-BC, CCRN;
Geri Seavey, BSM, MHA; John A. Spertus, MD, MPH, FACC, FAHA
Background—The American Heart Association (AHA) statement has recommended routine screening for depression in
coronary artery disease with a 2-stage implementation of the Patient Health Questionnaire (PHQ). Because there is little
evidence on feasibility, accuracy, and impact of such a program on depression recognition in coronary patients, the AHA
recommendation has met substantial debate and criticism.
Methods and Results—Before the AHA statement was released, the Mid America Heart and Vascular Institute (MAHVI)
had implemented a depression screening protocol for patients with acute myocardial infarction that was virtually
identical to the AHA recommendations. To (1) evaluate this MAHVI quality improvement initiative, (2) compare
MAHVI depression recognition rates with those of other hospitals, and (3) examine health care providers’
implementation feedback, we compared the results of the MAHVI screening program with data from a parallel
prospective acute myocardial infarction registry and interviewed MAHVI providers. Depressive symptoms (PHQ-2,
PHQ-9) were assessed among 503 MAHVI acute myocardial infarction patients and compared with concurrent
depression assessments among 3533 patients at 23 US centers without a screening protocol. A qualitative summary of
providers’ suggestions for improvement was also generated. A total of 135 (26.8%) eligible MAHVI patients did not
get screened. Among screened patients, 90.9% depressed (PHQ-9 10) patients were recognized. The agreement
between the screening and registry data using the full PHQ-9 was 61.5% for positive cases (PHQ-9 10) but only 35.6%
for the PHQ-2 alone. Although MAHVI had a slightly higher overall depression recognition rate (38.3%) than other
centers not using a depression screening protocol (31.5%), the difference was not statistically significant (P0.31). Staff
feedback suggested that a single-stage screening protocol with continuous feedback could improve compliance.
Conclusions—In this early effort to implement a depression screening protocol, a large proportion of patients did not get
screened, and only a modest impact on depression recognition rates was realized. Simplifying the protocol by using
the PHQ-9 alone and providing more support and feedback may improve the rates of depression detection and
treatment. (Circ Cardiovasc Qual Outcomes. 2011;4:283-292.)
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Depression is a common comorbidity in patients withacute myocardial infarction (AMI), and is associated
with adverse long-term outcomes.1–3 It is also well docu-
mented that the majority of patients with coronary artery
disease (CAD) with significant depression are not recognized
at the time of their AMI.4,5 Accordingly, there has been
increasing pressure to improve depression recognition and
treatment in CAD, including the incorporation of depression
screening recommendations into guidelines for the manage-
ment of acute and chronic CAD.6,7 The American Heart
Association (AHA) recently published a scientific statement
emphasizing the importance of depression screening in CAD
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and advocating an explicit 2-step protocol for routine clinical
practice using the Patient Health Questionnaire (PHQ).6
Given the prevalence of depression in CAD patients1,8 and the
fact that treating depression can improve both depressive
symptoms and quality of life,9 the AHA recommendations
would appear to be an important potential advance in clinical
care. Congruent with the logic of the AHA, a multidisci-
plinary team at Saint Luke’s Mid America Heart and Vascu-
lar Institute (MAHVI) designed and implemented a depres-
sion screening protocol in April 2005. This protocol was
implemented as part of routine clinical AMI care after prior
evaluations had indicated that depression recognition rates for
hospitalized AMI patients at MAHVI were low (25%).4
WHAT IS KNOWN
● The American Heart Association published a scien-
tific statement in 2008 to increase the awareness on
depression in coronary heart disease, suggesting the
use of a 2-step depression screening protocol using
the 2-item Patient Health Questionnaire (PHQ), fol-
lowed by the 9-item PHQ when screened positive, to
facilitate the recognition of depression in routine
clinical practice.
WHAT THE STUDY ADDS
● Having adopted a similar routine screening protocol
in an acute myocardial infarction setting and using
parallel PHQ registry data in the same patients, this
study demonstrates that 1 in 4 patients did not get
screened; patients with the highest risk of depres-
sion—women and those with prior cardiac disease—
were particularly missed.
● Relying on the full PHQ-9 instrument instead of the
2-step protocol may be more practical and render
more reproducible and accurate screening results, as
the agreement on a positive screen for depression
was low for the PHQ-2, but better when relying on
the full PHQ-9 instrument when comparing routine
screening data and parallel registry data in the same
acute myocardial infarction patients as a control.
● Depression remains widely recognized in acute myo-
cardial infarction centers across the United States;
although the institution that adopted the routine
screening protocol had comparable overall depres-
sion recognition rates as compared with 23 centers
that did not have a protocol in place, depression
recognition rates in those who underwent the routine
depression screening protocol were 90%.
● Feedback from nursing and clinical staff working
with the 2-step depression screening protocol in
routine clinical care conveyed a need for better
support, continued education and feedback, and a
simplified process supported by psychiatric or psy-
chological staff.
Recently, however, significant criticism of the AHA rec-
ommendations for widespread depression screening has been
raised. These include concerns about the feasibility, accuracy,
and consequences of ubiquitous depression screening, which
are currently unknown.10–12 Given doubts about the potential
for routine depression screening in CAD patients to improve
depression recognition or treatment, more evidence on the
feasibility and outcomes (eg, depression recognition) of
routine depression screening is needed. We sought to address
this gap in knowledge by (1) evaluating the performance of
the implemented depression screening protocol within
MAHVI, including feasibility and validity against concurrent
assessments by trained interviewers; (2) comparing MAHVI
current depression recognition rates with depression recogni-
tion rates at 23 other US centers that did not have a depression
screening protocol in place; and (3) assessing MAHVI
providers’ perspectives on the implementation of the depres-
sion screening protocol. Given the concerns about routine
depression screening in the setting of AMI, as proposed in the
2008 AHA advisory,6 the evaluation of a real-world experi-
ence with a comparable depression protocol could provide
valuable feedback both with respect to the potential of the
AHA recommendations to improve depression recognition
and to highlight opportunities to better implement depression
recognition protocols in AMI patients.
Methods
Participants and Study Design
The primary objective was to report a single-center experience of the
implementation and performance of a formal depression screening
protocol (Figure 1, objective 1). This protocol was implemented at
Saint Luke’s MAHVI, Kansas City, MO, on April 1, 2005, and was
consistent with the AHA Advisory that was subsequently published
in 2008.6 Concurrent with the implementation of this screening
protocol, AMI patients from MAHVI—together with AMI patients
from 23 other US hospitals—were consecutively enrolled be-
tween April 11, 2005, and December 31, 2008, into the prospec-
tive multicenter Translational Research Investigating Underlying
disparities in acute Myocardial infarction Patients’ Health Status
(TRIUMPH) study.
The group of patients screened within MAHVI will be referred to
as “MAHVI”; MAHVI patients who underwent parallel depression
assessments within TRIUMPH will be denoted as “TRIUMPH-
MAHVI”; and the remaining group of patients that were enrolled for
all other centers in the TRIUMPH registry will be referred to as
“TRIUMPH-ALL” (Figure 2).
Patients in the TRIUMPH registry were eligible for inclusion if
they were 18 years or older, had elevated cardiac enzymes
(troponin-I or creatinine kinase-MB) within 24 hours of hospital
admission, and had supporting evidence suggestive of AMI, includ-
ing prolonged ischemic symptoms or ECG ST changes. Patients
were excluded if they were transferred to the participating hospital
from another facility 24 hours after initial presentation, were
incarcerated, refused participation, were unable to provide consent,
did not speak English or Spanish, or died or were discharged before
being contacted by the investigators. Demographic, clinical, and
psychological data for all TRIUMPH patients were collected from
chart abstraction and standardized baseline interviews by trained
hospital research staff during the index AMI admission. All partic-
ipants provided written informed consent, and the study protocol was
approved by the institutional review board at each participating
center.
To evaluate the performance of the depression screening protocol
(Figure 1, objective 1), data on depressive symptoms obtained from
the MAHVI screening protocol were analyzed for those patients
(TRIUMPH-MAHVI) whose depressive symptoms were similarly
assessed in the TRIUMPH registry, so that the concordance between
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the 2 assessments could be evaluated. Next, to provide a context for
interpreting MAHVI recognition rates, we compared MAHVI de-
pression recognition rates with those from the remaining TRIUMPH
sites (TRIUMPH-ALL) that had not implemented a formal depres-
sion screening protocol (Figure 1, objective 2). Finally, a descriptive
approach was adopted to evaluate postimplementation feedback on
the MAHVI screening protocol and to explore what health care
providers perceived as barriers for the implementation and how the
protocol might be improved. (Figure 1, objective 3).
Measures
MAHVI Depression Screening Protocol
As part of a quality-of-care initiative prepared by a multidisciplinary
team (clinicians, researchers, and quality managers), a standardized
2-step depression screening protocol was designed and implemented
at MAHVI in patients who were on an acute coronary syndrome care
management pathway (online-only Data Supplement).13 This path-
way was incorporated into the MAHVI AMI pathway, which
mandated depression screening by nursing staff for each patient
during their index admission. This protocol required the 2-item
PHQ-2 to be administered as a first step13 in defining whether the
patient was at risk for major depressive symptoms and to determine
whether the full PHQ-9 was required. Specifically, as soon as
patients were medically stabilized, patients were asked whether over
the past 2 weeks, (1) they have been feeling down, depressed, or
hopeless and (2) whether they felt little interest or pleasure in doing
things they normally would have enjoyed. Items on the PHQ-2 are
answered along a 4-point Likert scale (0not at all to 3nearly
every day), using a cutoff of 1 on the PHQ-2, a sensitivity of 91%,
and a specificity of 64% for the diagnosis of major depression has
been established in CAD patients.14 Scores 1 automatically led to
the next step of the screening protocol—the administration of the full
PHQ-9—which was performed immediately after completion of the
PHQ-2.
The PHQ-9 is a validated tool for depression screening that
incorporates each of the 9 Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition criteria,15–17 and of which the first 2
items comprise the PHQ-2. Similar to the PHQ-2, 4-item Likert
scales are used and responses are summed to create a score between
0 and 27 points. A PHQ-9 score of 10 has a sensitivity and
specificity rate of 88% for major depression.18–20 Depending on the
PHQ-9 sum score, the MAHVI depression screening protocol rec-
ommended different actions (online-only Data Supplement). The
required steps were that the nursing staff would notify the physician
that patients had a clinically relevant score on the PHQ-9 and place
order sheets in the patients’ chart. Physicians would then indicate the
appropriate depression treatment plan on the patient’s chart and had
to include this information in the discharge letter. To facilitate these
steps, preprinted order sheets were inserted by nursing staff to be
selected and signed by the clinician, and a preformatted macro of
recommendations was available to clinicians at the time of discharge
summary dictation. Treatment options were selected by clinicians
and included the following: (1) pharmacy consultations to recom-
mend and initiate antidepressant medications, (2) social services
consultations for depression outpatient treatment options, (3) nursing
staff provision of educational materials about depression, including
the opportunity to view an educational video, (4) chaplain consulta-
tion, and (5) in-hospital psychiatry consultations. The last option was
mandatory when a patient indicated suicidal ideation.
Depression Screening in the TRIUMPH Study
Parallel with the implementation of the MAHVI protocol, a multi-
center, prospective registry of AMI patients’ outcomes was con-
ducted at MAHVI and 23 other centers. Data collectors at each
center were trained in the administration of the PHQ, and this was
prospectively implemented at each center in each consenting AMI
patient. For the TRIUMPH registry data, depressive symptoms were
assessed with the full PHQ-9. Interviews were conducted after
patients were medically stabilized.
Depression Recognition
Depression recognition rates were prospectively documented within
the TRIUMPH study. To be classified as recognized, trained data
abstractors looked through the physician notes, discharge diagnoses,
discharge medications (to screen for the use of antidepressant
medications), and discharge summaries for any documentation that
the patient’s significant depressive symptoms or depression was
being recognized during the index AMI. To ensure that we did not
misclassify the use of antidepressive medications as indicating
depression recognition, patients who were prescribed antidepressant
medications solely for the purposes of smoking cessation or
neuralgic pains (n24) were not classified as having recognized
depression.
Figure 1. Main objectives and data sources of the study.
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This information on depression recognition was available within
the TRIUMPH registry and was used to determine the proportion of
recognized depressed patients that were screened within the MAHVI
screening protocol (Figure 1, objective 1) and to compare MAHVI
overall depression recognition rates with depression recognition rates
across TRIUMPH-ALL centers, 23 centers that did not have a formal
depression screening protocol in place (Figure 1, objective 2).
Perceived Barriers and Opportunities for
Depression Screening
Qualitative data were obtained from a convenience sample of
MAHVI health care providers to identify how well the quality-
improvement protocol had been received in daily clinical practice
(Figure 1, objective 3). The convenience sample consisted of 3
nurses, a social worker, 2 nurse practitioners, 3 medical residents,
and 2 cardiologists who were recruited between August 1, 2009, and
September 31, 2009. Postimplementation feedback was documented
using a standardized, open-ended interview approach with the
following 2 questions being asked to all interviewees: (1) “What is
your experience with the acute coronary syndrome depression
screening protocol?” and (2) “Do you have any suggestions to
optimize the acute coronary syndrome depression screening proto-
col?” The health care providers were all interviewed in person and
interviews were led by 3 interviewers (K.N. and K.S. performed all
interviews with the nurses and social worker, A.A. interviewed the
physicians and other health care providers). Interviews ranged from
10 to 20 minutes in length. Data were recorded by taking notes
during the interview.
Statistical Analyses
Evaluate the Performance of Depression Screening
Protocol Within MAHVI
Numbers of patients who did and who did not receive screening at
MAHVI and reasons for not screening were evaluated. To compare
baseline characteristics of patients who were screened per MAHVI
depression screening protocol and those who were not, Student t tests
(for normally distributed continuous variables) and Wilcoxon tests
(for continuous variables not following a normal distribution) and 2
or Fisher exacts tests for categorical variables were used as
appropriate.
Next, for MAHVI patients who received routine depression
screening in the hospital and had a positive PHQ-2 screen, the
proportion of patients in the following PHQ-9 score categories were
provided: PHQ-9 score 5 (no depressive symptoms); PHQ-9 score
5 to 9 (mild depressive symptoms); and PHQ-9 score 10 (moderate
to severe depressive symptoms). Similarly, we described parallel
PHQ-2 and PHQ-9 registry data obtained for the TRIUMPH-
MAHVI patients.
The concordance between the PHQ-2 MAHVI screening and
TRIUMPH-MAHVI registry data were determined by (1) generating
cross-comparisons (for PHQ-2 1 across the MAHVI screening and
TRIUMPH-MAHVI registry data; using the McNemar test), (2)
Figure 2. Overview of screening process and registry data.
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determining the test-retest reliability (correlating continuous PHQ-2
MAHVI screening and TRIUMPH-MAHVI registry data), and (3)
calculating the Cohen  coefficient (defined as the agreement
between the MAHVI screening and TRIUMPH-MAHVI registry
data, each of which classified a patient’s responses on the PHQ-2 as
“positive” [ie, presence of clinically relevant depressive symptoms;
PHQ-2 1] or “negative” [ie, absence of clinically relevant depres-
sive symptoms; PHQ-20]).21,22 Similarly, the concordance be-
tween the MAHVI screening and TRIUMPH-MAHVI registry data
were determined for the PHQ-9 data: (1) cross-comparisons (for
PHQ-9 10 across the MAHVI screening and TRIUMPH-MAHVI
registry data; using the McNemar test) were performed; (2) the test
reliability was performed; and (3) Cohen  coefficient was calcu-
lated. Finally, MAHVI depression recognition rates are described for
patients who were screened and who had clinically relevant depres-
sive symptoms (PHQ-9 score 10).
Contextualize MAHVI Overall Depression
Recognition Rates
Overall depression recognition rates for MAHVI (including screened
and unscreened patients) and for the TRIUMPH-ALL group (ie, 23
other hospitals from the TRIUMPH registry for which no systematic
screening protocol was in place) were summarized by the mean rate
of recognition among patients with PHQ-9 10 during the
TRIUMPH interviews. To test for the statistical difference between the
depression recognition rate at MAHVI and the TRIUMPH-ALL sites, a
hierarchical logistic regression model, adjusting for clustering by
site, was constructed to evaluate the effect of having a program in
place on depression recognition. All statistical analyses were con-
ducted with SAS software version 9.2 (SAS Institute Inc, Cary, NC).
All statistical tests were 2-tailed, and probability values 0.05 were
considered statistically significant.
Document Health Care Providers’ Perspectives on
MAHVI Depression Screening Protocol
Field notes obtained from the interviews were reviewed and were
searched for the presence of common themes regarding reported
barriers and opportunities for improvement of the depression proto-
col. The identified categories were named by the researchers (A.A.,
D.B., K.N., K.G., K.S.), and responses were categorized accordingly.
For both the implementation barriers and opportunities for improve-
ment of the depression screening protocol, the top 5 themes were
identified.
Results
Performance of Depression Screening Protocol
Within MAHVI
Success of Implementation
A total of 503 AMI patients from MAHVI were eligible for
parallel depression assessment—consisting of the in-hospital
depression screening per standardized protocol (MAHVI
patients) and the depression data obtained from the concur-
rent TRIUMPH registry (TRIUMPH-MAHVI patients)—
during their index AMI admission. The mean age of this
cohort was 5811 years, and 29% were female. Among these
patients, more than 1 in 4 patients (26.8%) did not receive
routine screening during their hospital stay (Table 1 and
Figure 2). Median time from admission to depression screen-
ing per protocol (MAHVI group) was 1.0 days (interquartile
range, 0.0 to 2.0), slightly shorter than the median time from
AMI admission to depression assessment within the parallel
TRIUMPH registry (TRIUMPH-MAHVI), which was 2.0
days (interquartile range, 1.0 to 3.0 days) (P0.0001).
Compared with MAHVI patients who did receive screen-
ing, a greater proportion of nonscreened MAHVI patients was
female, had a history of AMI, angina, or lung disease, and had
an in-hospital cardiac arrest. These patients were also less
likely to have higher PHQ-9 scores within TRIUMPH, to
present with an ST-elevation AMI and were less likely to
undergo an in-hospital percutaneous coronary intervention
(Table 1).
For the majority of nonscreened MAHVI patients, no valid
reason for nonscreening could be found, with a change in the
patients’ clinical pathway shortly after admission being the
most reported reason as to why patients did not receive
screening (Figure 2, left). Other reasons for nonscreening
included patients who were going for surgery and patients
being too sick at the time of screening.
Validity of MAHVI Screening and TRIUMPH-MAHVI
Registry Data
Of those who were screened per in-hospital MAHVI depres-
sion protocol, 20.4% had a positive PHQ-2 screen (PHQ-2
1), of which 30.1% classified for clinically relevant depres-
sive symptoms, with a PHQ-9 score 10 (Figure 2, left).
From the TRIUMPH-MAHVI registry data obtained
within the same MAHVI patients (Figure 2, right), it became
evident that among those who did not receive clinical
depression screening, almost half (47.4%) screened positive
on the PHQ-2, and of these patients, more than 1 in 3 patients
(35.9%) had clinically relevant depressive symptoms with a
PHQ-9 score 10.
Table 2 describes the concordance (column percentages are
provided) in scoring between the MAHVI screening and
TRIUMPH-MAHVI registry data for the PHQ-2 and PHQ-9
data. When comparing PHQ-2 data obtained from the
MAHVI clinical screening protocol versus the TRIUMPH-
MAHVI registry data, the concordance between positive
cases (PHQ-2 1) was low-moderate; 35.6% (95% confi-
dence interval, 28.2% to 42.9%) of patients who screened
positive based on the MAHVI inpatient clinical screening
protocol also had a positive PHQ-2 screen in the TRIUMPH-
MAHVI registry data, whereas the concordance for nega-
tive cases was much higher (91.7%) (Table 2). The
interobserver variation was substantial, as expressed by a 
statistic of 0.29, judged to indicate only fair agreement.23
The correlation between the continuous PHQ-2 MAHVI
screening and PHQ-2 TRIUMPH-MAHVI registry scores
was r0.43 (P0.01), which was judged to be moderate.
The McNemar test indicated that there was a significant
difference between the 2 different assessments (MAHVI
screening and TRIUMPH-MAHVI registry data) using the
PHQ-2 (P0.0001).
In contrast to the low-moderate concordance between
MAHVI and TRIUMPH-MAHVI PHQ-2 data, the agreement
between PHQ-9 data from the 2 assessments was 61.5% (95%
confidence interval, 42.8% to 80.2%) for the positive cases
(PHQ-9 10) and 87.2% for the negative cases. The 
coefficient was 0.51 and the correlation between continuous
PHQ-9 scores from MAHVI clinical screening and
TRIUMPH-MAHVI registry data were r0.54 (P0.01),
which were both judged to indicate moderate agreement.23
The McNemar test indicated that there was no difference
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between the 2 different assessments (screening and registry
data) using the PHQ-9 (P0.32).
Proportion of Recognized Depressed MAHVI
Patients Who Were Screened
For 9 in 10 screened MAHVI patients (90.9%) with clinically
relevant depressive symptoms (PHQ-9 10), further action
(“recognized” depressed patients) was undertaken, meaning
that they received a diagnosis of depression in the hospital
chart, were assigned a diagnosis of depression at hospital
discharge, were prescribed depression treatment, or were
referred for further depression management at discharge
(Figure 2, bottom left).
Table 1. Baseline Characteristics of Patients Who Did and
Who Did Not Receive Routine Depression Screening During
Index AMI Hospitalization: Data Collected From the MAHVI









Age, y, meanSD 58.111.4 59.311.1 0.27
Female sex, n (%) 98 (26.6) 49 (36.3) 0.04
Race, n (%) 0.62
White/Caucasian 330 (89.7) 120 (88.9)
Black/African American 31 (8.4) 14 (10.4)
Other 7 (1.9) 1 (0.7)
Socioeconomic factors, n (%)
Married 239 (65.1) 81 (60.0) 0.29
Greater than high school
education
224 (61.0) 86 (63.7) 0.59
Having no insurance 54 (14.5) 18 (13.3) 0.74
Working full- or part-time 2229 (62.7) 79 (58.5) 0.39
Medical history, n (%)
Hypercholesterolemia 176 (47.8) 63 (46.7) 0.82
Hypertension 207 (56.3) 85 (63.0) 0.18
Peripheral arterial disease 17 (4.6) 8 (5.9) 0.55
Diabetes mellitus 73 (19.8) 27 (20.0) 0.97
Prior AMI 27 (7.3) 25 (18.5) 0.001
Prior angina 15 (4.1) 14 (10.4) 0.007
Prior CABG 29 (7.9) 12 (8.9) 0.71
Prior PCI 61 (16.6) 27 (20.0) 0.37
Prior stroke 10 (2.7) 6 (4.4) 0.39
Chronic renal failure 11 (3.0) 5 (3.7) 0.78
Chronic lung disease 19 (5.2) 14 (10.4) 0.04
Chronic heart failure 11 (3.0) 3 (2.2) 0.77
Cancer (other than skin) 23 (6.3) 7 (5.2) 0.66
Smoked within last 30 d 149 (41.2) 60 (44.8) 0.47




AMI admission, n (%)
ST-elevation MI, n (%) 247 (67.1) 64 (47.4) 0.001
Ejection fraction  40%,
n (%)
48 (13.0) 24 (17.8) 0.18
Killip class, n (%) 0.16
I (no heart failure) 344 (93.7) 121 (89.6)
II (heart failure) 17 (4.6) 9 (6.7)
III (pulmonary edema) 4 (1.1) 5 (3.7)





Initial heart rate, beats per
minute, meanSD
79.219.0 80.322.8 0.62
Hospital length of stay,
median (interquartile
range)











In-hospital PCI 332 (90.2) 100 (74.1) 0.001
Thrombolytic therapy 29 (7.9) 5 (3.7) 0.10
In-hospital complications,
n (%)
Bleeding 81 (22.0) 37 (27.4) 0.21
Cardiac arrest 3 (0.8) 5 (3.7) 0.04
Cardiogenic shock 16 (4.3) 8 (5.9) 0.46
CVA 1 (0.3) 0 (0.0) 1.00
AMI 0 (0.0) 1 (0.7) 0.27
Dialysis 1 (0.3) 1 (0.7) 0.47
Depressive symptoms and
history




requiring treatment, n (%)
14 (3.8) 6 (4.4) 0.75
Currently taking medications
or receiving counselling
for depression, n (%)
40 (10.9) 16 (11.9) 0.75
CABG indicates coronary artery bypass grafting; PCI, percutaneous coronary
interventions; ACE, angiotensin-converting enzyme; and CVA, cerebrovascular
accident.
Table 2. Congruency Between PHQ-2 and PHQ-9 MAHVI




PHQ-20 PHQ-2 1 Total n
PHQ-20 188 (91.7%) 105 (64.4%) 293
PHQ-2 1 17 (8.3%) 58 (35.6%) 75
Total n 205 163 368
PHQ-9 10 PHQ-9 10 Total n
PHQ-9 10 41 (87.2%) 10 (38.5%) 51
PHQ-9 10 6 (12.8%) 16 (61.5%) 22
Total n 47 26 73
*Data are represented as n (%); column percentages are provided.
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Interinstitutional Comparison of MAHVI Overall
Depression Recognition Rates
Depressive symptoms were assessed among a total of 3533
AMI patients enrolled from the 23 TRIUMPH centers that did
not have a formal screening protocol, in addition to the 503
patients enrolled from MAHVI. Of the total TRIUMPH-ALL
patients assessed (n4036), 752 (18.6%) had clinically rele-
vant depressive symptoms (PHQ 10). The average overall
depression recognition rate among those with a PHQ score
10 across TRIUMPH sites was 31.5%, with a range
between 0% and 62.5% (Figure 3). The overall proportion of
depressed patients (including screened and nonscreened pa-
tients) being recognized within MAHVI was 38.3% and did
not significantly differ from the average recognition rate
(P0.31) across sites. Comparisons with site-adjusted means
confirmed these findings.
Health Care Providers’ Perspectives on MAHVI
Depression Screening Protocol
Perceived Barriers to Implementing the Depression
Screening Protocol
Responses to the interview questions of nursing and clinical
staff working with the MAHVI depression screening protocol
were categorized into the most frequently reported barriers
preventing the successful completion of the depression
screening protocol. Themes included “competing priorities in
a short length of stay” (eg, “last on priority list”), “protocol
and logistic issues” (eg, “multiple steps make it difficult”),
“concerns about patients’ reactions” (eg, “older people get
upset”), “lack of ownership/responsibility about process” (eg,
“wonder if we are stepping on toes of primary care physi-
cians”), and “lack of education and feedback” (eg, “vaguely
remember initial education”) were the 5 most-reported barri-
ers (see Table 3 for a complete overview, by profession, and
examples of comments).
Other more infrequently articulated barriers referred to
“role confusion about responsibilities” (eg, “Should they see
a psychiatrist in the hospital, follow up with their primary
care physician or psychiatrist, or should I give them an
antidepressant?” [said by a cardiologist]), “health care pro-
viders’ assumptions/biases” (eg, “patients have to be moti-
vated” [said by nurse]), or “unfamiliarity/feeling unqualified
to work with mental disease” (eg, “not sure cardiologists are
qualified to treat depression” [said by cardiologist]).
Perceived Opportunities to Improving the Depression
Screening Protocol
Nursing and clinical staff were also invited to express their
views on how they think the process could be improved and
what opportunities there are toward that end. The 5 most-
reported opportunities referred to providing “more education”
(eg, “Provide more education at start of rotation”), the
implementation of an “automatic psychiatry consult” when
patients screened positive (eg, “Make psychiatry referral
Figure 3. Variation of proportion of patients being recognized as depressed in hospital chart across sites within the TRIUMPH Registry.
Site 1 denotes the MAHVI, the site where the formal screening protocol was implemented. The average depression recognition rate is
indicated in the dashed horizontal line.
Smolderen et al Depression Screening in AMI 289
automatic for positive screens”), “improving the visibility of
the protocol” (eg, “Please order sheet in with progress
notes/sticker”), “providing more reinforcement/feedback” to
sustain interest in the process (eg, “Need follow-up educa-
tion”), and the incorporation of the screening protocol in
already existing “chart audits” (eg, “Consider including the
screening as a part of the chart audits for other documentation
issues”) (see Table 4 for complete overview by profession
and examples of comments). Less frequent suggestions for
improvement included “having 2 nurses to sign off” (eg,
“Consider having 2 nurses sign off to ensure that it is done”
[said by nurse practitioner]) and “provide clinical directions
for different depressive symptom classifications” (eg, “Con-
sider better guidance on what to do for different PHQ scores”
[said by cardiologist]).
Discussion
In light of the controversy surrounding depression screening
and the AHA recommendation that this should be routinely
performed in CAD patients,11,12 this study provides unique
real-world insights into the feasibility, validity, conse-
quences, and opportunities for improvement of the AHA
advisory recommendations. Moreover, concurrent assess-
ments from a parallel registry allowed for the evaluation of
the performance of the depression screening protocol and the
comparison of depression recognition rates of a center that
used the protocol with 23 other centers that did not use a
formal process of depression screening. As such, this study is
the first to report on how routine screening—as proposed in
the recent AHA guidelines6—affects depression recognition.
Despite the intent to provide routine screening to all AMI
patients as part of a quality-of-care improvement initiative,
more than 1 in 4 patients were not screened, suggesting only
modest feasibility in implementation and demanding further
insights into how to further improve routine depression
screening. Underscoring the importance of screening, how-
ever, we found that if patients were screened per hospital
protocol and a positive case was identified, a clinical response
to the diagnosis was undertaken in 9 of 10 cases. The consensus
on the “positive cases”—or those with significant depressive
symptoms—between MAHVI clinically driven depression rec-
ognition protocol and the MAHVI-TRIUMPH–based assess-
ments—was disappointing, especially with the PHQ-2 instru-
ment. We also found that although our 38% depression
recognition rate was substantially better than our previously
reported rate of 25%,4 MAHVI current recognition rates were
similar to those of 23 other US centers without a formal
screening protocol. Finally, interviews with nursing and
clinical staff elucidated that time constraints, failure to pay
attention to all steps of the protocol, feeling uncomfortable or
not responsible for addressing patients’ mental health, and
lack of education and feedback were important barriers to
successful completion of the protocol. These clinicians sug-
gested that a more simplified depression screening protocol
with the entire PHQ-9, with more follow-up and feedback on
Table 3. Most Reported Barriers by Clinicians, Nurses, and
Other Health Professionals Involved in MAHVI Routine
Depression Screening Protocol
Theme Examples of Comments
1. Competing priorities
especially in an era of short
length of stay
“Too many things to pay attention to”
resident
“Last on the priority list” nurse
“Fighting against time” social worker
2. Protocol logistics/process
issues/multiple steps
“Order sets not always on chart”
resident
“Sometimes sticker is missed” nurse
practitioner
“Multiple steps make it difficult” nurse
3. Concerned about patients’
reactions/resistance about
screening/consult
“Older people get upset” nurse
“Patients are overwhelmed already”
nurse
“I sometimes rephrase” nurse
4. Feel not responsible/lack of
ownership about process
“Wonder if we are stepping on toes of
primary care physicians” cardiologist
“I consider the sticker to be
documentation” cardiologist
“The more the process is taken out of my
hands, the better and faster the patient
will get the appropriate care” cardiologist
5. Education and feedback
about protocol
“More follow-up education and feedback
to the staff is needed” cardiologist
“Vaguely remember initial education”
resident
“Some nurses are not aware of the
protocol” nurse
Table 4. Most Reported Suggestions by Clinicians, Nurses,
and Other Health Professionals to Improve MAHVI Routine
Depression Screening Protocol
Theme Example of Comments
1. More education “Consider focusing education to those
cardiologists that round more often in the
hospital” cardiologist”
“More education at start of rotation”
resident





“Consider automatic psychiatry consult”
cardiologist
“Make psychiatry referral automatic for
positive screens” resident
“Why can’t there be an automatic consult,




“Stickers are small, hard to see” resident
“Place order sheet in with progress
notes/sticker” cardiologist
“Consider placing the stickers on a different





“Need follow-up education” resident
“Give more education nurse
“Worked at the beginning, but need to
re-fresh” social worker
5. Include in chart
audits
“Consider including the screening as a part of
the chart audits for other documentation
issues” nurse practitioner
“Add to core measure sheet” nurse
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performance, might be helpful and could improve the screen-
ing protocol.
These findings supplement a large body of research dem-
onstrating that depression after AMI is associated with
adverse outcomes, including suboptimal health status out-
comes,24,25 and worse prognosis as compared with nonde-
pressed counterparts.3,26,27 It also extends the insights from
several intervention trials and clinical care initiatives seeking
to address this problem.9,28–31 All of these prior studies apply
to CAD patients who were actually identified as having
significant depressive symptoms, but these studies were not
able to focus on the problem of unrecognized depressive
symptoms in real-world practice. Our findings, in a contem-
porary multicenter AMI population, reveal that almost 7 of 10
patients with significant depressive symptoms (PHQ-9 score
10) are not recognized and are thus not even eligible for
treatment of this common and burdensome comorbidity,
regardless of the potential impact of treatment on patients’
cardiovascular outcomes. Unfortunately, although the AHA
advisory proposes a clinically rational approach to improving
recognition, we have identified significant limitations in its
implementation at our center and more refinement to define
the optimal approach is needed. Thus our data support some
of the concerns of critics of the AHA recommendations.10,11
From our real-world experience, we learned 4 important
lessons. First, a substantial proportion did not get screening,
and the parallel TRIUMPH registry data indicated that many
of these unscreened patients had significant depressive symp-
toms. Among unscreened patients, there was a greater pro-
portion of women and patients with a prior cardiac history,
vulnerable groups of patients at increased risk for having
depression.1,32 Prioritized action will need to go into more
complete implementation to improve the recognition of de-
pression among unscreened patients. Second, given that the
agreement on the identified “positive cases” was disappoint-
ing with the brief 2-item instrument, as compared with the
results from the full PHQ-9 instrument, we believe that the
full PHQ-9 should be used for depression screening. Standard
completion of the PHQ-9 takes minimal additional time once
the PHQ-2 is being performed, simplifies the process of
screening, and appears to be more reproducible and accurate.
Additionally, despite the user-friendliness and strong perfor-
mance characteristics to detect a major depressive disorder,
relatively little is known about the performance characteris-
tics of depression screening instruments in specific popula-
tions, such as AMI patients.33 The limited concordance
between different assessments during patients’ AMI admis-
sion—especially when using the PHQ-2—requires additional
research specifically with regard to the variability in results
due to its timing and mode of administration in a population
wherein the acute condition itself challenges the evaluation of
patients’ mood status. Third, studying the site variability on
overall depression recognition across 24 US centers illus-
trates that depression remains widely unrecognized, given the
fact that 9 of 10 of MAHVI patients who were screened per
protocol were actually recognized. Given the encouraging
promise of collaborative care and stepped-care models for
depression treatment, as exemplified for patients’ health
status in the Bypassing the Blues Trial9 and potentially
patients’ prognosis in the Coronary Psychosocial Evaluation
Studies (COPES) intervention trial, our data underscore the
opportunity to improve the recognition and treatment of
depression.31 Fourth, the identified barriers and suggestions
raised by the nursing and clinical staff collectively point to a
need for better support, follow-up education, and feedback
and a simplified process supported by psychiatric or psycho-
logical staff. These findings are consistent with prior research
in primary care implicating that depression screening proto-
cols whereby staff is sufficiently supported and the process is
coordinated by a qualified case manager will be the best way
to optimize chances of success in improving outcomes for
somatic patients with comorbid depression.34,35
Our results should be interpreted in the context of several
potential limitations. First, because our quality-improvement
initiative concerns a single center, our findings may not
translate to other centers’ experiences. Nevertheless, the
insights from practitioners on how to improve the process—
particularly with regular education and feedback on perfor-
mance—may assist other institutions in developing more
effective protocols. Second, the reported observations, partic-
ularly regarding the validity of the screening protocol, may
have been influenced by differences in the timing of assess-
ments and changes in patients’ depressive symptoms during
the acute recovery from an AMI. Although some have argued
that depression screening should occur in an outpatient
setting, when patients are more stable, a robust literature
documents the prognostic significance of depressive symp-
toms at the time of an AMI 3,26,25 and identifying and
preventing patients’ risks for adverse outcomes is a corner-
stone of AMI care. Finally, we restricted our analysis to the
cohort of MAHVI AMI patients who were also enrolled in
TRIUMPH and did not assess the performance in those not
enrolled.
In conclusion, the real-world evaluation of a 2-step depres-
sion screening protocol in AMI patients—consistent with the
recent AHA advisory—and its comparison with parallel
registry data suggested the following: in those who were
screened, the initial screen—using the PHQ-2 instrument—
may not be as accurate as one using the full PHQ-9 instru-
ment. Feedback from clinical and nursing staff supported this
notion from a more practical standpoint, as noted in the
suggestions that a simplified process, with fewer steps, would
be preferred. Unfortunately, our experience also documented
that many patients were missed by the screening protocol, and
centers wishing to implement a systematic depression screen-
ing protocol will need to find novel strategies with which to
reinforce and sustain such a program in clinical practice.
Finally, continuing efforts, both in research and in clinical
practice, are needed to further refine strategies that may help
to improve detection, care, and outcomes of depressed AMI
patients. By improving the recognition of significant depres-
sive symptoms and implementing evolving treatment strate-
gies, an important opportunity to further optimize the care
and outcomes of depressed AMI patients may be realized.
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